Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ultraviolet Rays | 5 | 2017 | 198 | 0.570 |
Why?
|
| Sweat Gland Diseases | 1 | 2016 | 3 | 0.510 |
Why?
|
| Eccrine Glands | 1 | 2016 | 4 | 0.510 |
Why?
|
| Radiodermatitis | 1 | 2016 | 10 | 0.510 |
Why?
|
| Erythema | 2 | 2016 | 33 | 0.510 |
Why?
|
| Skin Neoplasms | 8 | 2012 | 625 | 0.470 |
Why?
|
| Indoles | 1 | 2016 | 317 | 0.440 |
Why?
|
| Sulfonamides | 1 | 2016 | 338 | 0.420 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 657 | 0.400 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2012 | 4 | 0.390 |
Why?
|
| Leukemic Infiltration | 1 | 2012 | 14 | 0.390 |
Why?
|
| Conjunctival Diseases | 1 | 2012 | 6 | 0.390 |
Why?
|
| Immunosuppressive Agents | 3 | 2012 | 995 | 0.330 |
Why?
|
| Tongue Neoplasms | 2 | 2005 | 51 | 0.280 |
Why?
|
| Azathioprine | 1 | 2008 | 125 | 0.280 |
Why?
|
| Mohs Surgery | 2 | 2005 | 28 | 0.280 |
Why?
|
| Pemphigoid, Bullous | 2 | 2022 | 12 | 0.270 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2422 | 0.230 |
Why?
|
| Condylomata Acuminata | 1 | 2005 | 15 | 0.230 |
Why?
|
| Skin | 3 | 2017 | 605 | 0.200 |
Why?
|
| Pemphigus | 2 | 2012 | 14 | 0.190 |
Why?
|
| Lichen Planus | 1 | 2022 | 10 | 0.190 |
Why?
|
| DNA Damage | 3 | 2012 | 392 | 0.170 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2011 | 149 | 0.160 |
Why?
|
| DNA Repair | 2 | 2011 | 376 | 0.150 |
Why?
|
| Blister | 2 | 2022 | 8 | 0.140 |
Why?
|
| Keratinocytes | 4 | 2012 | 146 | 0.140 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 481 | 0.140 |
Why?
|
| DNA-Binding Proteins | 3 | 2012 | 1268 | 0.130 |
Why?
|
| Biopsy | 3 | 2016 | 1220 | 0.130 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2017 | 12 | 0.130 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1996 | 18 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 294 | 0.130 |
Why?
|
| Pruritus | 1 | 2016 | 30 | 0.130 |
Why?
|
| Metaplasia | 1 | 2016 | 39 | 0.130 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 61 | 0.130 |
Why?
|
| Immunoglobulin A | 1 | 1996 | 91 | 0.120 |
Why?
|
| Interleukin-2 | 1 | 1996 | 248 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 315 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 162 | 0.120 |
Why?
|
| Autophagy | 1 | 2017 | 177 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2017 | 237 | 0.110 |
Why?
|
| Tuberous Sclerosis | 1 | 2014 | 31 | 0.110 |
Why?
|
| Fibroma | 1 | 2014 | 33 | 0.110 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2011 | 96 | 0.110 |
Why?
|
| Exanthema | 1 | 2014 | 41 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2014 | 151 | 0.100 |
Why?
|
| Humans | 23 | 2022 | 96127 | 0.100 |
Why?
|
| Mycophenolic Acid | 2 | 2010 | 86 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2014 | 176 | 0.100 |
Why?
|
| Cyclophilin A | 1 | 2012 | 4 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 2463 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2014 | 202 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2012 | 304 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 269 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2012 | 242 | 0.090 |
Why?
|
| Keratosis, Actinic | 1 | 2011 | 13 | 0.090 |
Why?
|
| Keratosis, Seborrheic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Inflammation | 1 | 2017 | 1068 | 0.080 |
Why?
|
| Sirtuin 1 | 1 | 2010 | 37 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 356 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 1215 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2012 | 298 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 1829 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 147 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 192 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2006 | 11 | 0.060 |
Why?
|
| Sarcoma, Kaposi | 1 | 2006 | 18 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 2006 | 34 | 0.060 |
Why?
|
| Castleman Disease | 1 | 2006 | 13 | 0.060 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 368 | 0.060 |
Why?
|
| Ossification, Heterotopic | 1 | 2005 | 32 | 0.060 |
Why?
|
| Lymphangioma | 1 | 2005 | 15 | 0.060 |
Why?
|
| Male | 7 | 2016 | 45870 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2011 | 367 | 0.060 |
Why?
|
| Aged | 4 | 2016 | 20964 | 0.060 |
Why?
|
| Hemangioma | 1 | 2005 | 65 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2005 | 126 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1172 | 0.060 |
Why?
|
| Anesthesia, Local | 1 | 2004 | 28 | 0.050 |
Why?
|
| Epinephrine | 1 | 2004 | 92 | 0.050 |
Why?
|
| Nerve Block | 1 | 2004 | 52 | 0.050 |
Why?
|
| Fingers | 1 | 2004 | 70 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 247 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 366 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2005 | 274 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2005 | 180 | 0.050 |
Why?
|
| Incidence | 1 | 2008 | 1715 | 0.050 |
Why?
|
| Laser Therapy | 1 | 2005 | 151 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2642 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 150 | 0.050 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2003 | 2 | 0.050 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2003 | 7 | 0.050 |
Why?
|
| Scalp | 1 | 2003 | 72 | 0.050 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2003 | 43 | 0.050 |
Why?
|
| Risk Factors | 2 | 2014 | 5960 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2005 | 211 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 647 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2017 | 623 | 0.040 |
Why?
|
| Autoantibodies | 2 | 2012 | 281 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 611 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2014 | 301 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 188 | 0.040 |
Why?
|
| Base Sequence | 2 | 2017 | 2344 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 1192 | 0.040 |
Why?
|
| Female | 7 | 2014 | 50063 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2011 | 527 | 0.040 |
Why?
|
| Middle Aged | 4 | 2014 | 28363 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 2163 | 0.040 |
Why?
|
| Adult | 5 | 2014 | 28718 | 0.030 |
Why?
|
| Protein Kinases | 2 | 2011 | 216 | 0.030 |
Why?
|
| Mice | 4 | 2012 | 12562 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2017 | 74 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 30 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 70 | 0.030 |
Why?
|
| Lymphangiogenesis | 1 | 2017 | 41 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 100 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 89 | 0.030 |
Why?
|
| Epidermis | 1 | 2017 | 104 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 1469 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2017 | 132 | 0.030 |
Why?
|
| Animals | 5 | 2017 | 28945 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 145 | 0.030 |
Why?
|
| Dental Enamel | 1 | 2014 | 16 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2014 | 50 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 1105 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2014 | 76 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 90 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2014 | 9173 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 992 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 119 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 207 | 0.020 |
Why?
|
| Desmoglein 3 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Desmoglein 1 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 1561 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 79 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 872 | 0.020 |
Why?
|
| Thorax | 1 | 2012 | 80 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 886 | 0.020 |
Why?
|
| Papilloma | 1 | 2011 | 23 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2011 | 35 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1195 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 126 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2014 | 513 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 124 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2012 | 842 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 224 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2040 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 206 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1963 | 0.020 |
Why?
|
| RNA Interference | 1 | 2010 | 385 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 567 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1568 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 798 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1503 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1807 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 898 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 518 | 0.020 |
Why?
|
| Scleroderma, Localized | 1 | 2008 | 9 | 0.020 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2008 | 7 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1958 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 232 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 1020 | 0.020 |
Why?
|
| Genome | 1 | 2010 | 407 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2010 | 781 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1096 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1933 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2533 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2006 | 11 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 80 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2006 | 59 | 0.010 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2005 | 21 | 0.010 |
Why?
|
| Scapula | 1 | 2005 | 25 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2943 | 0.010 |
Why?
|
| Pregnancy | 1 | 2012 | 3240 | 0.010 |
Why?
|
| Adolescent | 2 | 2010 | 9896 | 0.010 |
Why?
|
| Incidental Findings | 1 | 2005 | 99 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 5585 | 0.010 |
Why?
|
| Lidocaine | 1 | 2004 | 67 | 0.010 |
Why?
|
| Forecasting | 1 | 2005 | 317 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 210 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 423 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 84 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2005 | 294 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 554 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 473 | 0.010 |
Why?
|
| Abdomen | 1 | 2003 | 127 | 0.010 |
Why?
|
| Carcinoma | 1 | 2005 | 449 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2003 | 193 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 3927 | 0.010 |
Why?
|
| Melanoma | 1 | 2005 | 497 | 0.010 |
Why?
|
| Reoperation | 1 | 2003 | 707 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 1178 | 0.010 |
Why?
|